Company intelligence / Profile preview

Legge Work

Somerset, New Jersey, United Statesnz.linkedin.com ↗

Ownership: Private
Employees: ~1001
Development stage: Other

Overview

Legend Biotech is a global leader in commercial-stage CAR-T therapies. Its lead product, ciltacabtagene autoleucel ("cilta-cel", marketed as CARVYKTI®), has demonstrated groundbreaking 5-year survival data in multiple myeloma at ASCO 2025. The company continues to expand its pipeline with new oncologic and hematologic therapeutics using various advanced cellular platforms[2][3][4].

Therapeutic areas: Oncology
Modalities: CAR-T cell therapyT cell receptor engineered T cell therapyNatural killer (NK) cell therapyCell therapy
Industry: Biotech

Partnerships

Janssen Pharmaceuticals / Johnson & Johnson – global collaboration for development and commercialization of ciltacabtagene autoleucel ("CARVYKTI")[3]

Beyond the preview

Go deeper on Legge Work.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Legge Work.

Explore the full profile